Sumitomo Pharma Oncology, Inc.
Records under this name other than the patents Sumitomo Pharma Oncology, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 24 patents it holds.
Back to Sumitomo Pharma Oncology, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,710,057 | Imidazo[1,2-b]pyridazine and Pyrazolo[1,5-a]pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 7,750,007 | Imidazo[1,2-beta]pyridazine and PYRAZOLO[1,5-Alpha]PYRIMIDINE Derivatives and Their Use as Protein Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 9,416,132 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,047,093 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,392,392 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,875,864 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,202,356 | JAK2 and ALK2 Inhibitors and Methods for Their Use Formerly held In force · High confidence | In force | High confidence | |
| US 10,752,594 | JAK1 and ALK2 inhibitors and methods for their use Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,471,456 | Formulations Comprising Heterocyclic Protein Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 11,793,802 | Treatment of acute myeloid leukemia (AML) with venetoclax failure Formerly held In force · USPTO record | In force | USPTO record |